The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study

Aim      To determine the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on kidney function in acute decompensated heart failure (ADHF).

Material and methods  A controlled randomized study on the dapagliflozin treatment in ADHF was performed. Patients were randomized to a main group (standard therapy supplemented with dapagliflozin) or a control group (standard therapy for ADHF). The primary endpoint was the development of acute kidney injury (AKI). 200 patients were included (mean age, 74±12 years; 51% men). 31% of patients had type 2 diabetes mellitus (DM2). Mean left ventricular ejection fraction (LV EF) was 47±14 %; in 44.5% of patients, LV EF was less than 45%. Median concentration of N-terminal pro-brain natriuretic peptide (NT-proBNP) was 5225 [3120; 9743] pg / ml, glomerular filtration rate (GFR) was 51 [38; 64] ml / min / 1.73 m2.

Results In-hospital mortality was 6.5%. Analysis of the dynamics of body weight loss showed significant differences (4200 [2925; 6300] g vs. 3000 [1113; 4850] g; p=0.011) in favor of the dapagliflozin group. The requirement for increasing the daily dose of furosemide and adding an another class diuretic (thiazide or acetazolamide) did not differ between the groups. However, median furosemide dose during the stay in the hospital was lower in the dapagliflozin group (80 [67; 120] mg vs. 102 [43; 120] mg; p=0.016). At 48 hours after randomization, GFR significantly decreased in the dapagliflozin group (–5.5 [–11; 3] ml/min/ 1.73 m2) compared to the control group (–0.3 [–4; 5] ml / min/1.73 m2, р=0.012). Despite this, GFR did not differ between the groups at discharge (51 [41; 66] ml/min/1.73 m2 and 49 [38; 67] ml/min/1.73 m2, respectively; p = 0.84). In the dapagliflozin group, frequency of AKI episodes was not increased compared to the control group (13 and 9.4%, respectively; p = 0.45).

Conclusion      The dapagliflozin treatment in ADHF is associated with more pronounced body weight loss and lower average doses of loop diuretics during the period of stay in the hospital, with no associated clinically significant impairment of renal function.

1. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. Cardiac Failure Review. 2017;3(1):7. DOI: 10.15420/cfr.2016:25:2

2. Funahashi Y, Chowdhury S, Eiwaz MB, Hutchens MP. Acute Cardiorenal Syndrome: Models and Heart-Kidney Connectors. Nephron. 2020;144(12):629–33. DOI: 10.1159/000509353

3. Palmiero G, Cesaro A, Vetrano E, Pafundi PC, Galiero R, Caturano A et al. Impact of SGLT2 Inhibitors on Heart Failure: From Pathophysiology to Clinical Effects. International Journal of Molecular Sciences. 2021;22(11):5863. DOI: 10.3390/ijms22115863

4. McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM et al. A trial to evaluate the effect of the sodium–glucose co‐transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA‐HF). European Journal of Heart Failure. 2019;21(5):665–75. DOI: 10.1002/ejhf.1432

5. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326–36. DOI: 10.1161/CIRCULATIONAHA.120.051783

6. Ferrannini G, Savarese G, Rydén L. Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility. Diabetes Research and Clinical Practice. 2021;175:108796. DOI: 10.1016/j.diabres.2021.108796

7. Damman K, Beusekamp JC, Boorsma EM, Swart HP, Smilde TDJ, Elvan A et al. Randomized, double‐blind, placebo‐controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA‐RESPONSE‐ AHF). European Journal of Heart Failure. 2020;22(4):713–22. DOI: 10.1002/ejhf.1713

8. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TDJ, Cleland JGF et al. Worsening Renal Function and Prognosis in Heart Failure: Systematic Review and Meta-Analysis. Journal of Cardiac Failure. 2007;13(8):599–608. DOI: 10.1016/j.cardfail.2007.04.008

9. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF, Dokainish H, Edvardsen T et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal – Cardiovascular Imaging. 2016;17(12):1321–60. DOI: 10.1093/ehjci/jew082

10. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368

11. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. Nephron Clinical Practice. 2012;120(4):c179–84. DOI: 10.1159/000339789

12. Vaduganathan M, Kumar V, Voors AA, Butler J. Unsolved challenges in diuretic therapy for acute heart failure: a focus on diuretic response. Expert Review of Cardiovascular Therapy. 2015;13(10):1075–8. DOI: 10.1586/14779072.2015.1087313

13. Tang WHW, Kiang A. Acute Cardiorenal Syndrome in Heart Failure: from Dogmas to Advances. Current Cardiology Reports. 2020;22(11):143. DOI: 10.1007/s11886-020-01384-0

14. Verbrugge FH, Martens P, Ameloot K, Haemels V, Penders J, Dupont M et al. Acetazolamide to increase natriuresis in congestive heart failure at high risk for diuretic resistance. European Journal of Heart Failure. 2019;21(11):1415–22. DOI: 10.1002/ejhf.1478

15. Kosiborod MN, Angermann CE, Collins SP, Teerlink JR, Ponikowski P, Biegus J et al. Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. Circulation. 2022;146(4):279–88. DOI: 10.1161/CIRCULATIONAHA.122.059725

16. Boorsma EM, Beusekamp JC, Maaten JM, Figarska SM, Danser AHJ, Veldhuisen DJ et al. Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure. European Journal of Heart Failure. 2021;23(1):68–78. DOI: 10.1002/ejhf.2066

17. Vallon V, Verma S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annual Review of Physiology. 2021;83(1):503–28. DOI: 10.1146/annurev-physiol-031620-095920

18. Bayes-Genis A, Iborra-Egea O, Spitaleri G, Domingo M, RevueltaLópez E, Codina P et al. Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence. Scientific Reports. 2021;11(1):12025. DOI: 10.1038/s41598-021-91546-z

19. Tadic M, Sala C, Saeed S, Grassi G, Mancia G, Rottbauer W et al. New antidiabetic therapy and HFpEF: light at the end of tunnel? Heart Failure Reviews. 2022;27(4):1137–46. DOI: 10.1007/s10741-021-10106-9

20. Savarese G, Uijl A, Lund LH, Anker SD, Asselbergs FW, Fitchett D et al. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure. 2021;27(8):888–95. DOI: 10.1016/j.cardfail.2021.05.012

21. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine. 2021;385(16):1451–61. DOI: 10.1056/NEJMoa2107038

22. Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal. 2022;43(5):416–26. DOI: 10.1093/eurheartj/ehab798